Learn more about the Commissioners
Saleh Aljadeeah
Saleh Aljadeeah is a Postdoctoral Researcher at the Institute of Tropical Medicine in Antwerp, Belgium. His work sits at the intersection of access to medicines, drug utilization research, and health systems in humanitarian and conflict-affected settings. He has led and co-led national and multi-country projects focused on medicine access for forcibly displaced populations and in fragile contexts. His work has received international recognition, including awards from the Konrad Adenauer Foundation, the University of Oxford, and the City of Bayreuth.
Dr. Aljadeeah holds a I hold a PhD in Drug Utilization Research (University of Bayreuth, Germany). an MSc in Evidence-Based Health Care (University of Oxford, UK), and a degree in Pharmacy (Damascus University, Syria).
Yusi Anggriani
Yusi Anggriani is a Professor in the Clinical and Community Pharmacy at Universitas Pancasila in Jakarta Indonesia. She is currently the director of the Centre for Pharmaceutical Policy and Services Studies (CEPHAS). She has experience working with the Ministry of Health, the Indonesian Food and Drug Agency, The National Health Insurance Bureau, and other National institutions for around 20 years in medicine access and pharmaceutical policy. She has been appointed as a member of the National Pricing Experts Committee (Ministry of Health) and Technical Advisory Group on Pricing Policies for Medicines (WHO). She also has experience conducting research on access to medicines, including medicine pricing policy with the World Health Organization and United Nations Development Program, Health Action International, and other international universities.
Brook K. Baker
Brook K. Baker is a Professor Emeritus at Northeastern U. School of Law. As a senior policy analyst for Health GAP (Global Access Project), Professor Baker has campaigned for access to medicines for HIV/AIDS, COVID-19, and other health conditions. He has consulted widely on IP, trade, and regulatory policies, including with multiple countries, the African Union, NEPAD, ASEAN, CARICOM, DfID, WHO, Millennium Development Goals Project, Global Fund, UNAIDS, UNDP, Unitaid, Medicines Patent Pool, Global Commission on HIV and the Law, ACT-Accelerator, and others. He has served as a key advisor, alternate and board member of the NGO delegation to Unitaid.
Esteban Burrone
Esteban Burrone has over 20 years of experience working in the field of access to health technologies. He is currently the Director of Policy, Strategy and Market Access of the Medicines Patent Pool (MPP), an institution he contributed to establishing in 2010 to promote access to affordable health products in low-and middle-income countries (LMICs), through licensing and technology transfer. Esteban holds a MSc. in Development Studies from the LSE and an MPH from the London School of Hygiene and Tropical Medicines.
Webpage: LinkedIn
Andy Gray
Andy Gray BPharm, MSc (Pharm), PhD, FPS, FFIP is a Senior Lecturer in the Division of Pharmacology, Discipline of Pharmaceutical Sciences, University of KwaZulu-Natal, Durban, South Africa. He is co-director of the WHO Collaborating Centre on Pharmaceutical Policy and Evidence Based Practice. He is also Honorary Senior Scientist: Consultant Pharmacist for the Centre for the AIDS Programme of Research in South Africa (CAPRISA). He was appointed to the South African National Essential Medicines List Committee in 2013 and chairs its Expert Review Committee. He currently serves on three technical advisory committees at the South African Health Products Regulatory Authority (SAHPRA). He is a Member of the WHO Expert Panel on Drug Policies and Management.
Ellen t' Hoen
Ellen ‘t Hoen, LLM PhD, is a lawyer and public health advocate. She is the director of Medicines Law & Policy. From 1999 until 2009 she was the director of policy for Médecins sans Frontières’ Access Campaign. In 2009 she joined UNITAID to set up the Medicines Patent Pool (MPP). She was the MPP’s first executive director until 2012. She has worked as an advisor to governments, NGOs and international organisations. She has published widely on medicines law and policy issues. Her book “Private Patents and Public Health: Changing intellectual property rules for public health” was awarded the Prix Prescrire in 2017 for being a “major reference work on access to medicines”. Between 2005 and 2021 she was listed 5 times as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property. In 2020, she was appointed Officer of the Order of Oranje-Nassau for her work on access to affordable medicines. She has a Masters of Laws from the University of Amsterdam and a PhD from the University of Groningen.
Dr. Aljadeeah holds a I hold a PhD in Drug Utilization Research (University of Bayreuth, Germany). an MSc in Evidence-Based Health Care (University of Oxford, UK), and a degree in Pharmacy (Damascus University, Syria).
Chittawan Poonsiri
Chittawan Poonsiri is a pharmacist by training, with early experience as a hospital pharmacist providing oncology care in Thailand. She is currently a researcher at the Health Intervention and Technology Assessment Program (HITAP), where her work focuses on economic evaluation and policy-relevant research to inform equitable health system decisions. Her research interests include Distributional Cost-Effectiveness Analysis (DCEA), methods to integrate equity into health technology assessment, and access to essential medicines. She also serves as part of the secretariat for the Health Economics Working Group under Thailand’s National List of Essential Medicines (NLEM), supporting evidence-informed and equity-oriented medicines policy.
Libby Roughead
Libby Roughead’s is Director of the Quality Use of Medicines and Pharmacy Research Centre, Adelaide University, and current Chair of the International Society to Improve Use of Medicines. Libby has led 75 national interventions to improve use of medicines in Australia. Libby is a Fellow of the International Society of Pharmacoepidemiology, a former Harkness Fellow in Health Care Policy and Practice, member of the Australian Government Drug Utilisation Sub-Committee and member of the Medication Safety and Quality Advisory Committee, Australian Commission on Safety and Quality in Health Care. Libby has served as a consultant to the World Health Organization.
Max Salcher
Maximilian Salcher-Konrad is a Senior Health Expert and Deputy Head of Pharmacoeconomics at Gesundheit Österreich GmbH (Austrian National Public Health Institute). He conducts research on medicine pricing, reimbursement, and procurement and supports pharmaceutical reform initiatives in the Austrian health system. His PhD, obtained at the London of School of Economics (LSE), examined uncertainty in regulatory decision-making and the role of non-randomised evidence in marketing authorisation. In his previous role as a Research Fellow at the LSE, his research focused on comparative effectiveness, methodological aspects of evidence generation, pharmaceutical regulation, and economic evaluation.
Sangeeta Sharma
Saleh Aljadeeah is a Postdoctoral Researcher at the Institute of Tropical Medicine in Antwerp, Belgium. His work sits at the intersection of access to medicines, drug utilization research, and health systems in humanitarian and conflict-affected settings. He has led and co-led national and multi-country projects focused on medicine access for forcibly displaced populations and in fragile contexts. His work has received international recognition, including awards from the Konrad Adenauer Foundation, the University of Oxford, and the City of Bayreuth.
Dr. Aljadeeah holds a I hold a PhD in Drug Utilization Research (University of Bayreuth, Germany). an MSc in Evidence-Based Health Care (University of Oxford, UK), and a degree in Pharmacy (Damascus University, Syria).
Fatima Suleman
Fatima Suleman is a Research Professor in the School of Health Sciences, University of KwaZulu-Natal and Co-Director: World Health Organization Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice. She is a former Prince Claus Chair of Development and Equity: Affordable (Bio)Therapeutics for Public Health (2016- 2018) at Utrecht University. Her work has concentrated in the area of pharmaceutical policy, with a focus on ensuring affordability and access to medicines. Her work has led to technical advice being provided on pharmaceutical policy for several countries in Africa and Asia in the last 17 years.
Jing Sun
Jing Sun is a Professor of Pharmaceutical Policy of the School of Health Policy and Management, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC). Her research areas focus on pharmaceutical policy analysis, specialized in pharmaco-economics and pharmaco-epidemiology.
Veronika Wirtz
Dr. Veronika J. Wirtz is a professor of Global Health at the Boston University School of Public Health, where she is also the Director of the World Health Organization Collaborating Center in Pharmaceutical Policy. Between 2014 and 2016, she was the Co-Chair and lead author of The Lancet Commission report Essential Medicines for Universal Health Coverage and is currently the Co-Chair of The Lancet Commission Accelerating Progress on Essential Medicines.
She is a visiting professor at the National Institute of Public Health (INSP), Mexico, where she was a faculty member between 2005 and 2012. Dr. Wirtz received her training as a pharmacist from Albert-Ludwigs-University in Freiburg, Germany and her Master of Science degree and her doctorate degree from the University of London, UK.
Olivier Wouters
Olivier J. Wouters, Ph.D., is an Associate Professor at Brown University’s School of Public Health and a visiting faculty member at Harvard Medical School. He was previously an Assistant Professor in the Department of Health Policy at the London School of Economics.
His research focuses on pharmaceutical economics and policy, particularly drug pricing and access to medicines in high- and middle-income countries. His work has been published in leading journals, including Health Affairs, JAMA, The Lancet, and The New England Journal of Medicine.
Dr. Wouters holds a Ph.D. in Health Policy and an M.Sc. in Health Economics, both from the London School of Economics.
Prashant Yadav
Prashant Yadav is a senior fellow for global health at the Council on Foreign Relations (CFR) and a globally recognized expert in healthcare supply chains, with extensive publications on health product manufacturing, procurement, and distribution. His work has appeared in the Financial Times, The Economist, Nature, The New York Times, The Wall Street Journal, and Foreign Affairs, and he has frequently appeared on NPR, BBC, CNN, CBS, and CNBC. He has worked at the Bill & Melinda Gates Foundation and held faculty roles at INSEAD, the MIT-Zaragoza Logistics Program, and the University of Michigan. He has received best paper awards from leading scientific bodies, serves on boards of global organizations and social enterprises, and has provided expert testimony before the U.S. Congress and other international legislative bodies. He holds degrees in chemical engineering, an MBA, and a PhD in Management Science.
Link to webpage: https://www.cfr.org/experts/prashant-yadav